1-(2,4-difluorophenyl)-1H-pyrazole-4-carbaldehyde | 1134705-53-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2,4-difluorophenyl)-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-(2,4-difluorophenyl)pyrazole-4-carbaldehyde
• CAS: 1134705-53-5
• 化学式: C₁₀H₆F₂N₂O
• 分子量: 208.167
• InChiKey: KHJNQQRBDAAYEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2,4-difluorophenyl)-1H-pyrazole-4-carbaldehyde 在 甲醇 、 sodium tetrahydroborate 、 氯化亚砜 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.58h， 生成 N'-(7-{[1-(2,4-difluorophenyl)-1H-pyrazol-4-yl]methyl}-5-[2-(trifluoromethyl)pyrimidin-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,N-dimethylformimidamide
  参考文献：
  名称：

  PYRROLOPYRIMIDINES AS CFTR POTENTIATORS

  摘要：

  本发明涉及式I的化合物，其中R1a、R1b、R2、R3、R4、W、Y和Z如本文所述，并且其药学上可接受的盐。这些化合物是囊性纤维化跨膜传导调节器（CFTR）的增效剂。本发明还揭示了包括该化合物的药物组合物，可选地与额外治疗剂结合，并通过给予这些化合物来增强哺乳动物（包括人类）CFTR的方法。这些化合物可用于治疗囊性纤维化（CF）、哮喘、支气管扩张、慢性阻塞性肺病（COPD）、便秘、糖尿病、干眼症、胰腺炎、鼻窦炎、Sjögren综合征和其他与CFTR相关的疾病。

  公开号：

  US20180141954A1
• 作为产物：
  描述：

  2,4-二氟苯肼 、 乌洛托品 在 三氟乙酸 作用下， 生成 1-(2,4-difluorophenyl)-1H-pyrazole-4-carbaldehyde
  参考文献：
  名称：

  22 苯基-1H-吡唑衍生物的核磁共振数据的完整分配

  摘要：

  22 1-苯基-1H-吡唑衍生物的 1H 和 13C NMR 化学位移和 J（1H/1H 和 1H/19F）耦合常数的完整分配是使用 1H 1D 和 1H、13C 2D gs-HSQC 的协同应用完成的和 gs-HMBC 实验。所有 1-苯基-1H-吡唑衍生物均按照Finar 及其同事的描述合成。甲酰化 1-苯基-1H-吡唑衍生物在达夫条件下进行。版权所有 © 2011 John Wiley & Sons, Ltd.

  DOI：

  10.1002/mrc.2773

文献信息

• Pyrrolopyrimidines as CFTR potentiators
  申请人：CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.

  公开号：US10301315B2

  公开（公告）日：2019-05-28

  The present invention relates to compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

  本发明涉及式 I 的化合物、 其中 R1a、R1b、R2、R3、R4、W、Y 和 Z 如本文所述，及其药学上可接受的盐。这些化合物是囊性纤维化跨膜传导调节器（CFTR）的增效剂。本发明还公开了包含该化合物的药物组合物（可选择与其他治疗剂组合），以及通过施用该化合物在哺乳动物（包括人类）体内增效 CFTR 的方法。这些化合物可用于治疗囊性纤维化 (CF)、哮喘、支气管扩张、慢性阻塞性肺病 (COPD)、便秘、糖尿病、干眼症、胰腺炎、鼻炎、Sjögren 综合征和其他 CFTR 相关疾病。
• Chemoselective and Regiospecific Formylation of 1-Phenyl-1<i>H</i>-pyrazoles Through the Duff Reaction
  作者：C. H. A. de Oliveira、L. M. Mairink、F. Pazini、L. M. Lião、A. L. de Oliveira、C. Viegas、V. de Oliveira、L. C. Cunha、F. G. F. Oliveira、J. L. Paz、M. N. Eberlin、Ricardo Menegatti

  DOI：10.1080/00397911.2012.657764

  日期：2013.6.18

  The synthesis of formylated 1-phenyl-1H-pyrazole derivatives under the Duff reaction conditions is reported. Our results indicate that 1-phenyl-1H-pyrazole systems containing electron-withdrawing and electron-donating substituents at the phenyl moiety react under the Duff reaction conditions to furnish formylated derivatives in good yields.
• Pyrrolopyrimidines as CFTR Potentiators
  申请人：Cystic Fibrosis Foundation

  公开号：US20210171534A1

  公开（公告）日：2021-06-10

  The present invention relates to methods of using compounds of Formula I, wherein R 1a , R 1b , R 2 , R 3 , R 4 , W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.
• [EN] PYRROLOPYRIMIDINES AS CFTR POTENTIATORS<br/>[FR] PYRROLOPYRIMIDINES UTILISÉES COMME POTENTIALISATEURS DE CFTR
  申请人：CYSTIC FIBROSIS FOUND THERAPEUTICS INC

  公开号：WO2018094137A1

  公开（公告）日：2018-05-24

  The present invention relates to compounds of Formula (I), wherein R1 a, R1 b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjogren's Syndrome, and other CFTR associated disorders.